Australia’s ChemGenex High On Leukemia Drug After Trial Results
This article was originally published in PharmAsia News
Executive SummaryChemGenex of Australia said the latest trial results of its omacetaxine drug to treat chronic myeloid leukemia are so promising it expects the medicine to be on the U.S. market by next March. The new results show an 85 percent remission rate for trial participants who are resistant to standard treatments, ChemGenex said. Analysts see the U.S. market for its drug worth $250 million in 2012 alone. CEO Greg Collier said that based on the positive results, the firm already is interviewing for a chief commercial officer to market the drug. (Click here for more
You may also be interested in...
All medtech in Brazil will soon be subject to standardized industrial tariffs and development-related fiscal incentives, following a reform of rules relating to ICT across all industries.